secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001193125-24-280125
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion secures $1.75M from praliciguat license amendment, signs olinciguat option deal
--------------------------------------------------------------------------------

- Akebia to pay Cyclerion $1.25M by Dec 31, 2024, and $500k by Sep 30, 2025; assumes IP costs after Q1 2025.
- Tiered royalties increased to mid-single-digit to 20% on net sales; some development milestones reduced.
- Exclusive license option for olinciguat granted to entity controlled by CVCO Therapeutics; grantee pays IP costs.
- Proceeds will fund CNS pipeline build; company plans to raise capital as needed to support product plans.
- Olinciguat option, if exercised, would complete monetization of Cyclerion's historical sGC stimulator portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312524280125/0001193125-24-280125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312524280125/d856941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-280125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer